Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Dormant
Current status date:
2018-09-07
Original market date: See footnote 1
2001-12-21
Product name:
MYOCET
DIN:
02245015
Product Monograph/Veterinary Labelling:
Date:
2006-06-07
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
SOPHERION THERAPEUTICS LLC
Po Box 477
East Brunswick
New Jersey
United States
08816-0477
Class:
Human
Dosage form(s):
Liposomes
Route(s) of administration:
Intravenous
Number of active ingredient(s):
1
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
10:00.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
L01DB01 DOXORUBICIN
Active ingredient group (AIG) number:See footnote5
0110825002
Active ingredient(s) See footnote8 | Strength |
---|---|
DOXORUBICIN HYDROCHLORIDE | 2 MG / ML |